Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics, Inc. (JANX)
:JANX
JANX Stock Chart & Stats
$34.69
-$2.71(-4.69%)
At close: 4:00 PM EST
$34.69
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$21.73 - $71.71
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.15M
Market Cap
$2.09B
Enterprise Value$549.53M
Total Cash (Recent Filing)$988.99M
Total Debt (Recent Filing)$22.66M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Mar 06, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,147,808
10 Day Avg. Volume1,146,887
30 Day Avg. Volume1,148,771
Financial Highlights & Ratios
PEG Ratio13.76
Price to Book (P/B)2.81
Price to Sales (P/S)271.80
P/FCF Ratio-65.15
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue54.95
Enterprise Value/Gross Profit57.85
Enterprise Value/Ebitda-4.19
Forecast
1Y Price Target
$75.42Price Target Upside117.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.01
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Clinical Trials SuccessJANX007 demonstrated a clean safety profile with predominantly grade 1-2 CRS, compared to other PSMA T-cell engagers that historically have reported higher rates of high grade cytokine release syndrome.
Financial PerformanceThe company reported collaboration revenue of $10.0M, significantly higher than the consensus estimated revenues of $2.9M.
Research And DevelopmentPreclinical programs unveiled at Janux's R&D day are expected to enter the clinic next year, potentially expanding their pipeline into new areas of oncology and autoimmune indications.
Bears Say
Financial LossJANX reported a Q3 net loss of $24.3MM and cash of $989MM.
Market CompetitionThe r/r mCRPC setting is highly competitive with multiple programs in the clinic with different mechanisms of action.
Regulatory And Safety UncertaintySafety data details were not provided in the latest update, which may introduce uncertainty about potential treatment risks.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $21.73 and its highest was $71.71 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $2.09B.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2026 which is in 96 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.222.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,147,808 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -7.606%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.42 (117.41% Upside)
$75.42 (117.41% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 275.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.72%
12-Months-Change
Fundamentals
Return on Equity
-12.48%
Trailing 12-Months
Asset Growth
47.44%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$75.42
▲(117.41% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
24.47% Insiders
22.41% Mutual Funds
2.93% Other Institutional Investors
40.47% Public Companies and Individual Investors